Add like
Add dislike
Add to saved papers

Pharmacokinetics and safety of tobramycin nebulization with the I-neb® and PARI-LC Plus® in children with cystic fibrosis: a randomized, crossover study.

AIMS: We aimed to compare the pharmacokinetics (PK) and safety profile of tobramycin inhalation solution (TIS) using the I-neb device to the standard PARI-LC® Plus nebulizer in children with cystic fibrosis (CF).

METHODS: A randomized, open-label, crossover study was performed. In two separate study visits blood samples from 22 children were collected following TIS nebulization with the I-neb (75 mg) and PARI-LC Plus (300 mg). Study visits were separated by one month, in which one of the study nebulizers was used twice daily. Tobramycin PK for both nebulizers was established using measured tobramycin concentrations and Bayesian pharmacokinetic modelling software. Hearing and renal function tests were performed to test for aminoglycoside associated toxicity. In addition to standard eGFR values, biomarkers for tubular injury (KIM-1 and NAG) were measured. Patient and nebulizer satisfaction were assessed.

RESULTS: Inhalations were well tolerated and serum trough concentrations below the predefined toxic limit were reached with no significant differences in PK parameters between nebulizers. Results of audiometry and eGFR revealed no abnormalities. Increased urinary NAG/creatinine ratios at visit 2 for both nebulizers suggest, however, TIS-induced subclinical tubular kidney injury. Nebulization time was 50% shorter and patient satisfaction was significantly higher with the I-neb.

CONCLUSIONS: Nebulization of 75 mg TIS with the I-neb in children with CF resulted in comparable systemic exposure to 300 mg TIS with the PARI-LC Plus and was well tolerated and preferred over the PARI-LC Plus. Long-term safety of TIS nebulization should be monitored clinically, especially regarding the effects on tubular kidney injury.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app